

ing to any one of claim **1** to **7** or **16**, a polypeptide according to any one of claims **8** to **14**, or an Fc region according to claim **15**.

18. An expression vector, or a plurality of expression vectors, comprising a nucleic acid or a plurality of nucleic acids according to claim **17**.

19. A cell comprising an antigen-binding molecule according to any one of claim **1** to **7** or **16**, a polypeptide according to any one of claims **8** to **14**, an Fc region according to claim **15**, a nucleic acid or a plurality of nucleic acids according to claim **17**, or an expression vector or a plurality of expression vectors according to claim **18**.

20. A method comprising culturing a cell comprising a nucleic acid or a plurality of nucleic acids according to claim **17**, or an expression vector or a plurality of expression vectors according to claim **18**, under conditions suitable for expression of the antigen-binding molecule, polypeptide or Fc region from the nucleic acid(s) or expression vector(s).

21. A composition comprising an antigen-binding molecule according to any one of claim **1** to **7** or **16**, a polypeptide according to any one of claims **8** to **14**, an Fc region according to claim **15**, a nucleic acid or a plurality of nucleic acids according to claim **17**, an expression vector or a plurality of expression vectors according to claim **18**, or a cell according to claim **19**.

22. An antigen-binding molecule according to any one of claim **1** to **7** or **16**, a polypeptide according to any one of claims **8** to **14**, an Fc region according to claim **15**, a nucleic acid or a plurality of nucleic acids according to claim **17**, an expression vector or a plurality of expression vectors according to claim **18**, a cell according to claim **19**, or a composition according to claim **21** for use in a method of medical treatment or prophylaxis.

23. An antigen-binding molecule according to any one of claim **1** to **7** or **16**, a polypeptide according to any one of claims **8** to **14**, an Fc region according to claim **15**, a nucleic acid or a plurality of nucleic acids according to claim **17**, an expression vector or a plurality of expression vectors according to claim **18**, a cell according to claim **19**, or a composition according to claim **21**, for use in a method of treatment or prevention of a cancer, an infectious disease or an autoimmune disease.

24. A method, optionally an in vitro method, of killing cells expressing a target antigen, comprising contacting cells expressing the target antigen with an antigen-binding molecule according to any one of claim **1** to **7** or **16**, a polypeptide according to any one of claims **8** to **14**, an Fc region according to claim **15**, a cell according to claim **19**, or a composition according to claim **21**.

* * * * *